Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial
B Olzowy, M Canis, JM Hempel, B Mazurek… - Otology & …, 2007 - journals.lww.com
B Olzowy, M Canis, JM Hempel, B Mazurek, M Suckfüll
Otology & Neurotology, 2007•journals.lww.comObjective: To test whether the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
atorvastatin can slow down the progression of presbycusis. Patients: Fifty patients 60-to 75-
years-old with presbycusis and moderately elevated serum cholesterol. Intervention (s): In a
double-blind design, patients were randomly assigned to treatment with either atorvastatin
(40 mg/d orally) or placebo. Main Outcome Measure (s): Pure-tone audiometry and tinnitus
evaluation at enrolment and after 7 and 13 months. Results: Development of hearing …
atorvastatin can slow down the progression of presbycusis. Patients: Fifty patients 60-to 75-
years-old with presbycusis and moderately elevated serum cholesterol. Intervention (s): In a
double-blind design, patients were randomly assigned to treatment with either atorvastatin
(40 mg/d orally) or placebo. Main Outcome Measure (s): Pure-tone audiometry and tinnitus
evaluation at enrolment and after 7 and 13 months. Results: Development of hearing …
Abstract
Objective:
To test whether the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor atorvastatin can slow down the progression of presbycusis.
Patients:
Fifty patients 60-to 75-years-old with presbycusis and moderately elevated serum cholesterol.
Intervention (s):
In a double-blind design, patients were randomly assigned to treatment with either atorvastatin (40 mg/d orally) or placebo.
Main Outcome Measure (s):
Pure-tone audiometry and tinnitus evaluation at enrolment and after 7 and 13 months.
Results:
Development of hearing thresholds after 7 and 13 months showed no significant differences between the groups. Tinnitus score continuously improved in the atorvastatin group (34.8 at 7 and 27.6 at 13 mo), whereas it slightly deteriorated in the placebo group (24.8 at 7 and 26.8 at 13 mo). The effect on tinnitus was a tendency without statistic significance (p= 0.0833).
Conclusion:
Atorvastatin had no effect on the development of hearing thresholds, but resulted in a trend toward a relief of tinnitus.
Lippincott Williams & Wilkins